What should be the dosage of Retevmo 80 mg capsule and what is it used for

 

Retevmo 80 mg capsule is a medication that is used for the treatment of certain types of cancer. The active ingredient in Retevmo is selpercatinib, which belongs to a class of drugs known as kinase inhibitors.

Dosage

The recommended dosage of Retevmo 80 mg capsule varies depending on the patient’s weight, age, and overall health condition. The doctor will determine the appropriate dose for each patient based on these factors.

Retevmo 80 mg capsule is usually taken orally twice a day with or without food. The capsule should be swallowed whole with a glass of water. Patients should not crush, chew, or open the capsule.

Uses

Retevmo 80 mg capsule is indicated for the treatment of advanced non-small cell lung cancer (NSCLC), thyroid cancer, and other solid tumors that have a specific genetic mutation. Retevmo is specifically used in patients whose cancer has spread to other parts of the body (metastasized) or cannot be surgically removed.

Non-Small Cell Lung Cancer

Retevmo 80 mg capsule is used for the treatment of advanced non-small cell lung cancer (NSCLC) that has a specific genetic mutation. The genetic mutation is called RET fusion-positive. This type of cancer is rare and accounts for less than 1% of all lung cancers. Retevmo has been shown to shrink tumors and slow the progression of the disease in patients with NSCLC.

Thyroid Cancer

Retevmo 80 mg capsule is also used for the treatment of advanced thyroid cancer that has a specific genetic mutation. The genetic mutation is called RET mutation-positive. This type of cancer is rare and accounts for about 10–20% of all thyroid cancers. Retevmo has been shown to shrink tumors and slow the progression of the disease in patients with thyroid cancer.

Other Solid Tumors

Retevmo 80 mg capsule is also used for the treatment of other solid tumors that have a specific genetic mutation. The genetic mutation is called RET fusion-positive. These tumors can occur in various parts of the body, including the pancreas, colon, and appendix. Retevmo has been shown to shrink tumors and slow the progression of the disease in patients with these types of tumors.

Side Effects

As with all medications, Retevmo 80 mg capsule may cause side effects in some patients. Common side effects of Retevmo include:

Diarrhea

Nausea

Vomiting

Constipation

Fatigue

Abdominal pain

Decreased appetite

Increased blood sugar levels

Patients should talk to their doctor if they experience any of these side effects or any other unusual symptoms while taking Retevmo.

Conclusion

Retevmo 80 mg capsule is a medication used for the treatment of advanced non-small cell lung cancer, thyroid cancer, and other solid tumors that have a specific genetic mutation. The medication has been shown to shrink tumors and slow the progression of the disease in patients with these types of cancer. Patients should talk to their doctor about the appropriate dosage and potential side effects of Retevmo before starting the medication.



Comments

Post a Comment

Popular posts from this blog

Treatment for Acute Myeloid Leukemia: IDHIFA (Enasidenib)

Image
  In the world of oncology, breakthroughs in targeted therapies have opened new avenues for the treatment of various types of cancer. One such remarkable advancement is the introduction of IDHIFA (Enasidenib), a medication that has shown great promise in the fight against acute myeloidleukemia (AML) . Understanding IDHIFA and AML:  IDHIFA, known by its generic name Enasidenib, is an oral medication that targets a specific mutation known as isocitrate dehydrogenase 2 (IDH2). Mutations in the IDH2 gene are found in approximately 12-20% of AML patients. These mutations lead to the production of an abnormal form of the IDH2 enzyme, which plays a significant role in the development and progression of AML. Approved Indication: IDHIFA is specifically indicated for the treatment of adult patients with relapsed or refractory AML harboring an IDH2 mutation. It is not intended for use in patients with other types of leukemia or those without the IDH2 mutation. Accessing IDHIFA: Obtaining IDHIFA
Read more

What Patients Should Know about Early Access Programs- AlleviareIndia

Image
  Introduction: In the world of medical research and development, new treatments, drugs, and therapies are constantly being developed to address various health conditions. However, the journey from initial development to final approval by regulatory authorities can be a lengthy process, leaving many patients eagerly awaiting access to potentially life-saving treatments. This is where Early Access Programs (EAPs) come into play. In this article, we will explore what patients should consider when participating in an Early Access Program. Understand the Purpose and Eligibility Criteria: Before considering participation in an Early Access Program, it's important to understand its purpose. EAPs are designed to provide access to investigational treatments for patients who have exhausted all other available options and have a serious or life-threatening condition. Familiarize yourself with the eligibility criteria to determine if you meet the necessary requirements. Discuss with
Read more

Abatacept (Orencia)

Image
Abatacept (Orencia) is often prescribed after failure of an anti-rheumatic agent (DMARD), such as methotrexate. But it can be used as first-line therapy. Ebetasip is used to reduce inflammatory symptoms such as swelling, pain, and stiffness. In the long term, it is expected to prevent joint deformity, therefore helping to maintain range of motion. It is often used in patients with moderate to severe rheumatoid arthritis who have not responded to one or more DMARDs, such as methotrexate, or other biologic drugs. DMARDs are usually tried first. Abatacept may be used alone or in combination with DMARDs, which makes it more potent, but not with other biologic drugs (such as TNF inhibitors). Its use in other diseases is still being studied. Unlike some other biologic drugs, abetacept does not block anti-inflammatory proteins such as TNF-alpha antagonists. Abatacept attaches to the surface of inflammatory cells and blocks communication between these cells. By blocking this communicatio
Read more